The market has been down on Cleveland BioLabs, Inc. (CBLI) stock recently. CBLI gets a Bearish score from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With CBLI Stock Today?
Cleveland BioLabs, Inc. (CBLI) stock is trading at $4.65 as of 9:45 AM on Thursday, May 13, a gain of $0.16, or 3.56% from the previous closing price of $4.49. The stock has traded between $4.53 and $4.87 so far today. Volume today is light. So far 1,601 shares have traded compared to average volume of 147,201 shares.
To see the top 5 stocks in the Biotechnology industry click here.
More About Cleveland BioLabs, Inc.
Cleveland BioLabs Inc is a biopharmaceutical company. The company is developing novel approaches to activate the immune system and address serious medical needs. Its proprietary platform of Toll-like immune receptor activators has applications in the mitigation of radiation injury and immuno-oncology. Its lead product candidate is entolimod, an immuno-stimulatory agent, which is developed as a radiation countermeasure and immunotherapy for oncology and other indications. Entolimod is a Toll-like receptor 5 (TLR5) agonist, which is developed as a radiation countermeasure for the prevention of death from Acute Radiation Syndrome (ARS), and as an oncology drug.
Click Here to get the full Stock Score Report on Cleveland BioLabs, Inc. (CBLI) Stock.
